Mithradote Bio, a San Diego, CA-based biotechnology company developing the first self-administered antidote against drink spiking, closed a $1m seed funding round.
The round was co-led by Taho Pharma and Vickers Venture Partners, and supported by development agreements with Haorui Pharmatech for API manufacturing and Taho Pharma for an oral delivery formulation.
The company intends to use the funds to advance development of M-101, a novel sublingual self-administered antidote against a spectrum of “date-rape” drugs, and initiate another pipeline program.
Led by Founder and CEO Sophia Lee, Mithradote Bio is a biopharmaceutical company with the aim to develop safe and effective products that protect intended targets of drug-facilitated sexual assault.
Commenting on the news, Sophia Lee said; “We are proud to be developing a convenient sublingual strip that allows for rapid absorption and drug neutralization, and can be easily taken if the need arises. With the support of our new investors and strategic development partners, we are excited to advance this meaningful program.”
FinSMEs
02/10/2024